{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:18:28Z","timestamp":1793488708584,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.rdc.2015.08.009","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T13:19:48Z","timestamp":1448284788000},"page":"75-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis"],"prefix":"10.1016","volume":"42","author":[{"given":"Eric L.","family":"Matteson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9860","key":"10.1016\/j.rdc.2015.08.009_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large-vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.009_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.009_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.009_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of PMR and GCA","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","article-title":"Visual prognosis in GCA","volume":"100","author":"Aiello","year":"1993","journal-title":"Ophthalmology"},{"issue":"6, Suppl 47","key":"10.1016\/j.rdc.2015.08.009_bib7","first-page":"137","article-title":"Management guidelines and outcome measures in giant cell arteritis (GCA)","volume":"25","author":"Warrington","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib8","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar2664","article-title":"Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study","volume":"11","author":"Warrington","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.009_bib9","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","article-title":"Large-vessel involvement in GCA: a population-based cohort study of the incidence-trends and prognosis","volume":"72","author":"Kermani","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9343(97)89458-2","article-title":"Long-term survival of patients with GCA in the American College of Rheumatology GCA classification criteria cohort","volume":"100","author":"Matteson","year":"1996","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.009_bib11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/40.11.1238","article-title":"Survival in PMR and temporal arteritis: a study of 398 cases and matched population controls","volume":"40","author":"Gran","year":"2001","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.009_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1024\/0301-1526\/a000096","article-title":"Patterns of extracranial involvement in newly diagnosed GCA assessed by physical examination, colour coded duplex sonography and FDG-PET","volume":"40","author":"Forster","year":"2011","journal-title":"Vasa"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.009_bib14","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/bjs.7252","article-title":"Role of ultrasonography in the diagnosis of temporal arteritis","volume":"97","author":"Ball","year":"2010","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1759720X13512256","article-title":"Role of ultrasound in the understanding and management of vasculitis","volume":"6","author":"Schmidt","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"10.1016\/j.rdc.2015.08.009_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","article-title":"Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study","volume":"60","author":"Caporali","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.009_bib17","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of GCA","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.009_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology"},{"issue":"2 Suppl 89","key":"10.1016\/j.rdc.2015.08.009_bib19","first-page":"S103","article-title":"Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study","volume":"33","author":"Patil","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.009_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03009740510017706","article-title":"The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis","volume":"34","author":"Buttgereit","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.009_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1\u20132","key":"10.1016\/j.rdc.2015.08.009_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2013.01.026","article-title":"Optimized glucocorticoid therapy: teaching old drugs new tricks","volume":"380","author":"Strehl","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.rdc.2015.08.009_bib23","series-title":"Endocrinology and metabolism","first-page":"912","article-title":"Glucocorticoid therapy","author":"Tyrrell","year":"1995"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.009_bib24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.009_bib25","first-page":"1265","article-title":"Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases","volume":"27","author":"Sanden","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.009_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1203\/00006450-200101000-00025","article-title":"Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases","volume":"49","author":"Andreae","year":"2001","journal-title":"Pediatr Res"},{"issue":"9678","key":"10.1016\/j.rdc.2015.08.009_bib27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.009_bib28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","article-title":"Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"S2","key":"10.1016\/j.rdc.2015.08.009_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/annrheumdis-2014-eular.2271","article-title":"Current evidence for therapeutic interventions in polymyalgia rheumatica (PMR): a systematic literature review informing the ACR\/EULAR recommendations for the management of PMR","volume":"73","author":"Dejaco","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib30","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib31","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2015.08.009_bib32","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"Van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.47.9.733","article-title":"Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients)","volume":"47","author":"Delecoeuillerie","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep395","article-title":"Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study","volume":"49","author":"Mackie","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2015.08.009_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3143\/geriatrics.23.469","article-title":"Report of 6 cases with polymyalgia rheumatica and a review of the literature","volume":"23","author":"Kanemaru","year":"1986","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"10.1016\/j.rdc.2015.08.009_bib37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/030097401753180327","article-title":"Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients","volume":"30","author":"Myklebust","year":"2001","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.009_bib39","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/rheumatology\/kes153","article-title":"Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis","volume":"51","author":"Hauenstein","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.009_bib40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.48.8.658","article-title":"Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months","volume":"48","author":"Kyle","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.009_bib41","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.009_bib42","first-page":"1484","article-title":"A\u00a0randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.009_bib43","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","article-title":"Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica","volume":"40","author":"Gabriel","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.009_bib44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.009_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib46","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.009_bib49","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.009_bib50","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.009_bib51","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"8","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.009_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/rheumatology\/37.4.464","article-title":"No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study","volume":"37","author":"Schaufelberger","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.009_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03009740500474537","article-title":"No additional steroid-sparing effect of cyclosporine A in giant cell arteritis","volume":"35","author":"Schaufelberger","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.009_bib55","first-page":"694","article-title":"Does dapsone have a role in the treatment of giant cell arteritis with regard to efficacy and toxicity?","volume":"11","author":"Lizon","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.009_bib56","doi-asserted-by":"crossref","first-page":"120638","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.009_bib57","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.009_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.009_bib59","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.009_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.009_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A\u00a0double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib62","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.009_bib63","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/annrheumdis-2013-204572","article-title":"Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study","volume":"73","author":"Prieto-Gonz\u00e1lez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.009_bib64","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in GCA","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.009_bib65","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with GCA","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.009_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01658100802669797","article-title":"Should we prescribe aspirin for patients with GCA? A review of the evidence","volume":"33","author":"Edwards","year":"2009","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.rdc.2015.08.009_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2015.08.009_bib68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","article-title":"Pneumocystis jiroveci pneumonia in GCA: a case series","volume":"63","author":"Kermani","year":"2011","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X15000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:40Z","timestamp":1760181280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X15000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889857X15000733"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.009","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}